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Patient Reported Outcomes Center of Excellence, Global Market Access, Primary Care, Pﬁzer Ltd, Surrey, UKA B S T R A C TObjective: To ascertain the frequency and types of patient-reported
outcome (PRO) violations made in US pharmaceutical promotional
materials between 2006 and 2012 and determine whether there were
increases in violation warnings after issuance of the Food and Drug
Administration (FDA) draft and ﬁnal PRO Guidance. Methods: All
warning letters (WLs) or notices of violation (NOVs) issued by the
FDA’s Ofﬁce of Prescription Drug Promotion were reviewed for PRO
violations (n ¼ 213). Each letter containing a PRO violation was
reviewed to determine the type of violation: 1) PRO measure not ﬁt
for purpose, 2) study design/interpretation of results, 3) statistical
analysis, and 4) no treatment beneﬁt. Results: Forty-one (19%) letters
contained information about PRO infringements. Noticeable spikes in
letters were shown in 2007 (37%) and 2010 (31%) after the issuance of
the draft and ﬁnal PRO Guidance, respectively. The most common
violation was PRO measure not ﬁt for purpose (54%), speciﬁcally: useee front matter Copyright & 2014, International S
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urrey KT207NS, UK.of individual items (45%), insufﬁcient evidence of content validity
(36%), and broadening of the claim beyond what the PRO measures
(27%). Issues with study design/interpretation of results were also
high (49%), particularly broadening of claim beyond what was meas-
ured in the trial (55%) and no PRO measure used (50%). Conclusions:
A ﬁfth of the letters issued to companies contained PRO violations,
with most related to poor selection of the PRO measure used or trying
to broaden the claim. More guidance from the Ofﬁce of Prescription
Drug Promotion about what is considered “substantial evidence” in
this area could help reduce the number of letters issued.
Keywords: Food and Drug Administration, patient-reported outcome,
PRO Guidance, promotional claim.
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Patient-reported outcome (PRO) measures are widely used in drug
development programs as primary or secondary end points. For
example, to assess the cardinal presenting symptom of a con-
dition (e.g., pain due to osteoarthritis, urinary urgency and
frequency due to overactive bladder) or to provide evidence that
a biological improvement relates to symptom relief from the
patient perspective (e.g., Asthma: FEV1 and breathlessness), or to
demonstrate the wider beneﬁt of a drug treatment on patients’
health-related quality of life (QOL). In a recent review by Gnana-
sakthy et al. [1] of US product labels, however, they found that it
is the former, symptom-based information, that is more widely
incorporated in medical product labels.
As with any efﬁcacy data, the promotion of PRO data to
physicians or consumers must adhere to Food and Drug Admin-
istration’s (FDA’s) “substantial evidence” requirement, whichmeans that the evidence is supported by two adequate and
well-controlled trials [2] and is usually ratiﬁed by the FDA by
including the information in the label, although it is still possible
to promote data if there is no label claim should the sponsor feel
that it has sufﬁcient data on ﬁle to fulﬁll the substantial evidence
requirement. To monitor such activity by pharmaceutical com-
panies, the FDA’s Ofﬁce of Prescription Drug Promotions (OPDP)
reviews promotional materials and takes action against any such
materials that are “false, lacking in fair balance, or otherwise
misleading” [3]. Monitoring occurs on prescription drug advertis-
ing and includes promotional exhibits and materials used at
major medical meetings and pharmaceutical conventions. Spon-
sors can request review by the OPDP of proposed promotional
materials before using the materials. Also, the OPDP reviews
complaints sent to it about alleged promotional violations.
Warning letters (WLs) are issued for violations of “regulatory
signiﬁcance” and is the most serious communication before theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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things as seizure of goods or a monetary ﬁne. The WL is a means
to prompt voluntary compliance with the Federal Food Drug and
Cosmetic Act. A notice of violation (NOV, or untitled letter) is very
similar and serious albeit there is no statement of potential
enforcement action as with the WL.
A review by Stewart and Neumann [4] of economic and QOL
promotional claims between 1997 and 2001 found that 4.9% of the
letters cited QOL violations, with the majority due to “lack of
substantial evidence.” This review was limited to only QOL and
well-being claims. Since that time there has been the issuance of the
FDA’s PRO Guidance (draft in 2006 and ﬁnal in 2009) detailing how
any patient-reported measure, deﬁned as “… any report of the
status of the patient’s health condition that comes directly from the
patient, without interpretation of the patients response by a
clinician or anyone else,” should be developed and implemented
in clinical trials to gain product labeling related to the PRO data [5].
As such, we undertook to review WLs and NOVs from 2006 until
2012, using the broader deﬁnition of PRO and not just QOL/well-
being claims as used by Stewart and Newman [4] to 1) determine
frequency and types of PRO warnings or violations and 2) ascertain
whether there were increases in PRO promotional material warnings
and violations since the release of the draft PRO Guidance in 2006.Methods
On the FDA Web site, full-text copies of all WLs and NOVs sent to
pharmaceutical companies are available for those issued from
1997, following the Freedom of Information Act. In the current
review, letters only from January 2006 until December 2012 were
obtained to coincide with the Draft Guidance for the use of PROs
in clinical trials release in 2006. The search was further narrowed
by focusing purely on the way evidence from PROs was used in
promotional materials, which was achieved by only reviewing
letters sent by the OPDP, formerly the Division of Drug Marketing,
Advertising and Communications. For this review, “PRO viola-
tion” was taken to mean any promotional violation using either a
patient-reported or a proxy-reported measure.
After reading a sample of letters, a data abstraction form was
developed. This included information regarding the date of the
letter, the drug product, indications of the product, the nature of
the letter (WL or NOV letter), and the PRO measure cited in the
violation (if stated). The actual promotional material was also
collected when possible. The category of media used as the
promotional material (e.g., Internet promotion, video, brochure,
professional telephone script, professional sales/detail aid, sell
sheet, ﬁle card, direct mail, journal advertisement, leave behind,
print advertisement, patient proﬁle card, television advertise-
ment, and e-mail), as well as the target audience (professionals,Table 1 – Number of WLs and NOV letters between Janua
Year Number of OPDP
letters
Number of letters with PRO
violations
P
2006 22 1
2007 19 7
2008 24 4
2009 40 4
2010 52 16
2011 31 3
2012 25 6
Total 213 41
NOV, notice of violation; OPDP, Ofﬁce of Prescription Drug Promotion; PRconsumers, or unspeciﬁed), was also noted in the form. The
therapeutic area for each WL/NOV was also captured.
In the coding of the types of PRO violations, categories were
derived from those used in a previous review examining the
reasons for rejection of PRO data in US product labels [6]. In the
current review, the PRO violations were similarly categorized as
follows:1.ry
erc
O,PRO measure Not Fit For Purpose (use of individual items from
a multi-item measure or to support complex claims; insufﬁ-
cient evidence of content validity; improper use of a PRO
measure; broadening of claim beyond what is measured by
the PRO measure; recall period; improvements not found in all
domains; not valid for entire population; not appropriate to
assess symptom resolution)2. Study Design or Interpretation of Results (no PRO assessment
of patient-reported claims; broadening of claims beyond what
was collected in the trial; open label)3. Statistical Analysis (not appropriately powered; no adjust-
ment for multiplicity; not prespeciﬁed; inappropriate
analyses)4. No Treatment Beneﬁt
The text of each letter issued between 2006 and 2012 (n ¼ 213)
was reviewed to determine whether there was a PRO violation.
Violations were then coded using one or more of the above
categories independently by L.A. and T.S. Agreement between the
two was high (95%) for both general classiﬁcation of the violation
—PRO measure not ﬁt for purpose, study design/interpretation of
results, statistical analysis, or no treatment beneﬁt—and for the
subtype of violation within these broader categories as listed
above. If there was disagreement between the two raters, the
letters were reviewed together to determine a ﬁnal classiﬁcation.Results
Of the letters reviewed (n ¼ 213), 19% contained a PRO violation
(n ¼ 41); 15 (37%) of these were WLs and 26 (63%) were NOV
letters (Table 1). After an initial increase from 1 to 7 letters
between 2006 (5%) and 2007 (37%) when the Draft PRO Guidance
was issued, and a spike in 2010, the year after the Guidance was
ﬁnalized, when 16 (31%) letters contained PRO violations, the
number of letters has stayed fairly constant at around 3 to 7
letters each year (see Table 1).
PRO violations were issued across a wide array of therapeutic
areas (see Table 2); pain drugs had the highest frequency (24%).
Most of the violations were “PRO measure not ﬁt for purpose”
(54%), followed by “study design/interpretation of results” (49%).2006 and December 2012.
entage of letters with PRO
violations
Number of
WLs
Number of
NOVs
5 1 0
37 3 4
17 3 1
10 2 2
31 5 11
10 1 2
24 0 6
19 15 26
patient-reported outcome; WL, warning letter.
Table 2 – Frequency of PRO WLs or NOVs by
therapeutic area.
Therapeutic area Number of WLs/NOVs
Addiction 1
Allergy 5
Antiviral 4
Cancer 2
Cardiovascular 2
Dental 1
Dermatology 3
Endocrine 1
Gastrointestinal 2
Gynecology 3
Neuroscience 3
Pain 10
Ophthalmology 1
Urology 3
Total 41
NOV, notice of violation; WL, warning letter.
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Within the PRO measure not ﬁt for purpose category, the most
prevalent violation in the NOV/WLs was use of an individual item
from a multi-item measure to make a claim or to support
complex claims (45%); for example,
According to the clinical studies section of the PI, the assess-
ment of efﬁcacy for the treatment of seasonal and perennial
allergic rhinitis was based on the 12-hour reﬂective total nasal
symptom score (rTNSS) in addition to the instantaneous total
nasal symptom score (iTNSS), where TNSS was calculated as
the sum of the patients’ scoring of the four individual
symptoms of rhinorrhea, nasal congestion, sneezing, and
nasal itching. The clinical studies used for the approval of
Astepro 0.15% evaluated a composite measure of symptoms
and did not speciﬁcally evaluate efﬁcacy for the individual
symptom of nasal congestion. Demonstrating an effect on the
composite total nasal symptom score does not represent a
clear effect on any individual component of the TNSS. [7]
Insufﬁcient evidence of content validity of the measure for
assessing the outcome of interest (36%) and broadening of theTable 3 – Communication media cited in PRO violations.
Medium Number %
Internet promotion 4 7
Video 6 11
Brochure 8 14
Professional sales/detail aid 12 22
Sell sheet 2 4
File card 2 4
Direct mail 2 4
Journal advertisement 3 5
Patient proﬁle card 2 4
E-mail 2 4
Other* 12 22
Total† 55 100
* Communication media types mentioned in one letter: branded story, st
blue book message, patient program, leave behind, print advertisemen
† Some letters cited violations in more than one type of communicationclaim beyond what the PRO measure could assess (27%) were also
often reasons for a NOV/WL.
Study Design/Interpretation of the Results
In study design/interpretation of results, all subcategories were
cited but “broadening of the claim beyond what was measured in
the trial” was mentioned most in 11 of the 20 NOV/WLs (55%), for
example,
claims like “. . . Chronic pain . . . can be inconvenient and can
keep you from your daily tasks.” Although Kadian may help
treat patients’ moderate to severe pain, the FDA was not
aware of substantial evidence or substantial clinical experi-
ence demonstrating that the magnitude of the effect the drug
has in alleviating pain, taken together with any drug-related
side effects patients may experience (such as the common
adverse events of drowsiness, dizziness, constipation and
nausea), results in an overall positive impact on a patient’s
work, physical and mental functioning, daily activities, or
enjoyment of life. In addition, the FDA was not aware of any
studies demonstrating that the level of pain reduction expe-
rienced by patients on Kadian therapy corresponds with a
positive impact on the outcomes claimed. [8]
Half of the letters also mentioned “claims without use of a
PRO” (50%), and 30% cited studies being open label as an issue.
Statistical Analysis
Fewer NOV/WLs speciﬁed statistical issues (24%) but, if they were,
it was mainly because of lack of prespeciﬁcation of the analyses
conducted (50%); for example,
Comparative claim of patient-reported incontinence meas-
ures, where evidence was based on an exploratory secondary
analysis of a secondary endpoint with no pre-speciﬁed anal-
ysis plan—does not constitute substantial evidence. [9]
Inappropriate analyses (40%) and multiplicity (30%) were also
frequently cited.
No Treatment Beneﬁt
Only 12% of the NOV/WLs were issued because of lack of treat-
ment beneﬁt being demonstrated for the claim being made.
More than half the NOV/WLs contained more than one PRO-
related violation (54%), the most common multiple violation (sixProfessional Consumer Unspeciﬁed
1 1 2
1 3 2
0 8 0
9 0 3
1 0 1
2 0 0
2 0 0
3 0 0
0 0 2
1 1 0
5 4 3
25 17 13
all cling, co-pay backer card, z-card, sign, unspeciﬁed advertisement,
t, television advertisement, telephone script.
media.
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claim beyond what was collected in the clinical trial. For example:
Claims misleadingly overstate the efﬁcacy of Vivitrol by
implying that the usual outcome of treatment with Vivitrol
is a positive effect on a patient’s interpersonal relationships,
emotional functioning, work productivity, productivity in
general, and overall quality of life. Claims of such treatment
beneﬁts must be supported by substantial evidence or sub-
stantial clinical experience as demonstrated through
adequate and well-controlled trial(s) using well-developed
instruments that reliably and validly measure the speciﬁc
concepts at issue. [10]
Additional examples across these types of violations can be
found in the online Appendix in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.03.1718.
Various forms of communication media were used for promo-
tional materials (Table 3). Violations primarily occurred in pro-
fessional sales and detail aids (22%), brochures (14%), and
videos (11%).Discussion
There are no speciﬁc guidelines detailing what represents an
inappropriate PRO promotional claim. Although the FDA PRO
Guidance [5] should provide some direction, it is not clear
whether the OPDP consistently draw on this Guidance or not
although it is apparent that there is some reference to the PRO
Guidance and likely dialogue with Study Endpoints and Labelling
Development Division due to the types of feedback provided to
sponsors. By reviewing the NOV/WLs over a 7-year period, after
the issuance of the PRO Draft Guidance, this has given us some
insight into how the OPDP monitors and addresses PRO viola-
tions. Reviewing the NOV/WLs, however, provides information
only about those cases in which there has been an infringement;
it does not provide the total frequency by which companies use
PRO data in promotional pieces. Determining this frequency
would be interesting and might be achieved by reviewing print
drug advertisements in major clinical journals as Neumann and
Bliss [11] did for health economic messaging, an area for further
research. Reviewing material already in print, however, is not
necessarily a guarantee that the OPDP has endorsed it as suitable
for promotion, which makes it difﬁcult for anyone trying to
ascertain whether the same level of rigor for obtaining a PRO
label claim is applied to promotional claims by the OPDP.
Overall, letters with PRO violations made up 19% of the total
number of letters issued by the OPDP to pharmaceutical compa-
nies between January 2006 and December 2012, which is sub-
stantially higher than the 5% seen between 1997 and 2001 [4].
This may be due to the broader deﬁnition of PRO used in this
study but may also, in part, be due to the FDA’s PRO Guidance,
which was issued in draft form in 2006 and then ﬁnalized in
December 2009. The PRO Guidance, however, is likely to have
caused some increase and is evidenced by the spikes in the
number of NOV/WLs containing PRO violations in 2007 (37%) and
2010 (31%). An alternative theory posited by Neumann and Bliss
[11] for an increase in health economic promotional violations in
2010 was President Obama’s appointment of Margaret A. Ham-
burg as FDA Commissioner, and her pledge to step up enforce-
ment of misleading industry practices, which could also
potentially explain the increase in PRO NOVs/WLs.
The biggest area of violation was around the PRO measure not
being ﬁt for the claim being made and this being predominantly
around the use of a single item from a multi-item measure, broad-
ening of the claim beyond what the PRO measures, and insufﬁcient
evidence of content validity. Interestingly, content validity is a largefocus of the FDA PRO Guidance and may have affected the reporting
of this type of violation. The use of single items from multi-item
measures is still common despite the FDA PRO Guidance, with four
out of six letters citing this issue in 2012. Overall though, broadening
of the claim either beyond what the PRO measured, or the clinical
trial measured, was by far the most prevalent violation, with 17 of
the 41 [41%] letters reporting this problem.
Perhaps somewhat surprisingly, there were instances in
which claims were being made without showing any statistically
signiﬁcant treatment beneﬁt in the PRO measures for that claim.
Pooling of data from clinical trials is commonly reported in the
literature to demonstrate treatment effect. The NOV/WLs clearly
highlighted, however, that this does not constitute substantial
evidence to support claims, particularly when the individual
trials have shown no treatment effect.
Overall, there was a fairly high level of PRO violation across the
NOV/WLs issued. Is this level of violation a reﬂection of pharma-
ceutical companies’ lack of understanding about what constitutes
substantial evidence or is it that some companies simply try to
push the boundaries to improve sales? In the latter case, it would be
an interesting exercise to analyze the effect of taking this course of
action. Alternatively, could it be that the FDA requires too stringent
evidence for PRO data or, maybe, it is also looking at the implied
nature of the promotional claim? Morris and Miller [12] posit that
PRO claims often represent an extension of the clinical effects of a
drug. In such cases, the data are intended for the clinical trials
section of the label, not the indication section, and thus they argue
that the same level of evidence as for obtaining an indication is not
necessary, stating that a single adequate and well-controlled study
should sufﬁce. They go on to suggest using Section 114 of the Food
and Drug Administration Modernization Act, which relates to
health economics data, as a guide for the level of evidence required
for PRO promotional claims when they are not part of the indication
per se. The Food and Drug Administration Modernization Act
proposed a more ﬂexible standard for health economic claims,
requiring “competent and reliable scientiﬁc evidence for support”
rather than “substantial evidence.” This same standard has also
been proposed for certain types of comparative effectiveness claims
[13,14]. Whatever the reason for the relatively high level of NOV/
WLs, a speciﬁc guideline on how PRO claims are reviewed would be
welcomed and would clarify what is permissible and would remove
some of the “gray” area surrounding this type of promotion.Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at http://dx.doi.org/10.1016/j.
jval.2014.03.1718 or, if a hard copy of article, at www.valuein
healthjournal.com/issues (select volume, issue, and article).
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